0%
Print report
Variant interpretation report

TP53 c.854A>T, p.Glu285Val

NM_000546.5:c.854A>T NP_000537.3:p.(Glu285Val) Missense · exon 8 View identifiers
Classification
Pathogenic

Variant description:

The TP53 NM_000546.5:c.854A>T (NP_000537.3:p.(Glu285Val)) missense variant has previously been reported in somatic cancers (COSMIC; COSV52676438, n = 35 times), and lies in a statistically significant hotspot (cancerhotspots.org). Experimental evidence: The VCEP worksheet pre-assigns PS3 because E285V is non-functional in Kato and LOF in three other eligible assays. Based on available guidelines, this variant is considered to be Pathogenic.

Five-step scale from benign to pathogenic. This variant is pathogenic. Select a step to read what it means.

Pathogenic.A pathogenic classification under the recorded framework.

In plain language

Gene-level background from the recorded interpretation.

About TP53

TP53 encodes the p53 tumor suppressor protein, a transcription factor that responds to cellular stress such as DNA damage by switching on genes that trigger cell cycle arrest, DNA repair, senescence, or programmed cell death. In healthy cells, p53 is kept at low levels by constant degradation, but stress signals stabilize and activate it to protect against damaged cells surviving and dividing. Inherited mutations in TP53 cause Li-Fraumeni syndrome, a condition marked by a high risk of developing multiple cancers at a young age. TP53 is the most commonly mutated gene across human cancers, and loss of its normal function promotes tumor growth, spread, drug resistance, and genomic instability.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is ClinGen TP53 VCEP v2.4. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 4 Benign evidence criteria: 0
Pathogenic criteria applied · 4
PS2Strong
PS2 · strong

Met at strong: two strongly associated childhood cancers contribute 4 PS2 points under the assumed-parentage path, meeting the VCEP's 4-7-point PS2 threshold.

PS3Strong
PS3 · strong

Met at strong: the VCEP worksheet pre-assigns PS3 because E285V is non-functional in Kato and LOF in three other eligible assays.

PM2Supporting
PM2 · supporting

Met at supporting: gnomAD v4.1 reports AF 0 (0/1,614,150 alleles), below the VCEP PM2 threshold of <0.00003.

PP3Moderate
PP3 · moderate

Met at moderate strength: VCEP Table S2 pre-assigns PP3_moderate for Class C65 and BayesDel 0.453942, exceeding the ≥0.16 threshold.

Benign criteria applied · 0

No benign criterion marked as applied in the recorded assessment.

Recorded classification: Pathogenic

Pathogenic: PS2 strong, PS3 strong, PM2 supporting, and PP3 moderate total 11 points under the TP53 Expert Panel's Version 2.4 framework.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
0 / 1,614,150 alleles

gnomAD v4.1: 0 / 1,614,150 alleles. Recorded AF 0. Recorded homozygote count 0.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0; MAF= 0.00000%, 0/251472 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 0; MAF= 0.00000%, 0/16254 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

No screenshot for this evidence
REVEL score
0.936 recorded score

Recorded REVEL score: 0.936. Refer to the recorded PP3/BP4 rationale for interpretation.

ClinVar submissions
1 reported laboratory submissions

1 Pathogenic. ClinVar API review status: criteria provided, single submitter.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB identified variant-specific curated literature and context relevant to functional review; biological-effect context: Loss-of-function; curated oncogenicity label: Oncogenic.

COSMIC
Cancer Hotspots
Somatic evidence
35 recorded samples

This variant has previously been reported in somatic cancers (COSMIC; COSV52676438, n = 35 times).

Cancer Hotspots

This variant lies in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under ClinGen TP53 VCEP v2.4, with the data and sources behind each one.

28 criteria with recorded statuses: 4 met · 6 not met · 6 not assessed · 12 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

The TP53 VCEP v2.4 supports PS2 Strong from 4 confirmed-de-novo points for one proband with a strongly associated LFS cancer; PM6 is not applicable because the VCEP dropped it.

PP1 and BS4 are not assessed because the available evidence contains no affected-relative segregation or non-segregation data.

Within this criterion group, PS4 is not met because the documented clinical observation contributes 0.5 points, below the VCEP Supporting threshold; PP4 is not met because the only reported VAF is 38%, outside 5-35%; PP5, BP5, and BP6 are VCEP Not Applicable.

Exact-variant literature was checked across c.854A>T, p.Glu285Val, and p.E285V; somatic tumor observations were not treated as germline case-control evidence.

PP3 is met at moderate strength from the governing TP53 VCEP per-variant assignment: Class C65, BayesDel 0.453942, PP3_moderate.

BP4 is not met because the governing VCEP excludes C65 missense variants and the BayesDel score is not below 0.16.

BP7 is not applicable because the variant is missense rather than synonymous or intronic.

Met · 4

PS2 StrongVCEPMet at strong: two strongly associated childhood cancers contribute 4 PS2 points under the assumed-parentage path, meeting the VCEP's 4-7-point PS2 threshold. Details ▾Hide ▴
Reasoning

The exact variant c.854A>T/p.E285V was reported as a de novo germline TP53 variant in a child whose parents were both negative for the mutation. The same proband had choroid plexus carcinoma and adrenocortical carcinoma in childhood. The governing VCEP table classifies both cancers as strongly associated LFS cancers and assigns 2 points per strongly associated cancer when maternity and paternity are assumed; therefore the two cancers contribute 4 points total. The VCEP PS2 point rule assigns PS2 Strong to 4-7 points. The publications do not document confirmed maternity and paternity, so the confirmed-parentage 4-point-per-cancer path is not used.

VCEP rule
2 points for probands with a strongly associated cancer when maternity and paternity are assumed ... Choroid plexus carcinoma ... Adrenocortical adenoma or carcinoma < 18 years of age ... 4-7 points
Evidence considered
  • Russell-Swetek et al. (PMID:18762572) reports the exact TP53 E285V variant as a de novo germline mutation in a child with choroid plexus carcinoma followed by adrenocortical carcinoma; the paper states: "No mutation was detected in either parent, suggesting that the E285V mutation arose de novo in the proband."
  • Wasserman et al. (PMID:25584008) independently lists E285V as a de novo mutation in a child with pediatric adrenocortical carcinoma and no significant family history; Table 2, pedigree 58 records "E285V | De novo | 8.9".
  • ClinGen TP53 VCEP Table of LFS Cancers and Points for PS2 and PP1 Code Application: choroid plexus carcinoma and adrenocortical adenoma or carcinoma under 18 years are strongly associated LFS cancers; with maternity and paternity assumed, each strongly associated cancer contributes 2 points, giving 4 points for this proband.
  • ClinGen TP53 VCEP PS2 rule in the case CSPEC: 4-7 points corresponds to PS2 Strong.
Still missing
  • No variant-specific entry for c.854A>T, p.Glu285Val, or p.E285V was found in Table-of-LFS-Cancers-and-Points-for-PS2-and-PP1-Code-Application.pdf; the file was searched directly and supplies the governing cancer categories and point rules rather than a variant-specific pre-assigned code.
  • The cited reports state that both parents tested negative but do not document confirmed maternity and paternity; consequently, the confirmed-parentage point values were not applied.
Sources
PS3 StrongVCEPMet at strong: the VCEP worksheet pre-assigns PS3 because E285V is non-functional in Kato and LOF in three other eligible assays. Details ▾Hide ▴
Reasoning

The TP53 VCEP Functional-worksheet.xlsx Supplementary Table S3 row for E285V lists Kato as Non-functional, Funk as LOF, Giacomelli as LOF, Kotler as LOF, and Kawaguchi as NA, with the pre-assigned functional code PS3. This directly satisfies the VCEP strong PS3 path of non-functional Kato data plus LOF by the majority of other eligible assays; the flowchart independently maps that pattern to PS3. The exact variant was also functionally tested in a promoter-reporter assay and colony-growth assay, where E285V was inactive and failed to suppress colony growth, and the cohort summary reports 8.9% of wild-type TP53 activity from Kato transactivation data.

VCEP rule
Non-functional on Kato et al. data **AND** loss of function (LOF) by the majority of other eligible assays
Evidence considered
  • ClinGen TP53 VCEP Functional-worksheet.xlsx, Supplementary Table S3, row E285V: Kato class Non-functional; Funk class LOF; Giacomelli class LOF; Kotler class LOF; Kawaguchi class NA; preliminary functional code PS3.
  • ClinGen TP53 VCEP functional-code flowchart: missense variants with Kato data that are non-functional in Kato and LOF by the majority of available assays receive PS3.
  • Russell-Swetek et al. 2008 (PMID:18762572), Functional Characterization of E285V, Fig. 3: the exact E285V mutant was inactive in a p53-responsive promoter-reporter assay; Fig. 4 reports failure to inhibit colony growth.
  • Wasserman et al. 2015 (PMID:25584008), Table 2, pedigree 58: E285V is reported with median TP53 activity of 8.9% of wild-type activity based on Kato transactivation data.
Sources
PM2 SupportingVCEPMet at supporting: gnomAD v4.1 reports AF 0 (0/1,614,150 alleles), below the VCEP PM2 threshold of <0.00003. Details ▾Hide ▴
Reasoning

The TP53 VCEP specifies PM2 at supporting strength when the variant allele frequency is less than 0.00003 in gnomAD or another large sequenced population; if multiple alleles occur within an ancestry group, that group's frequency must be less than 0.00004, while founder-effect groups are ignored. gnomAD v4.1 reports 0/1,614,150 total alleles (AF 0) and no homozygotes; every reported ancestry group also has zero alternate alleles, so no ancestry group has multiple observed alleles or exceeds the ancestry-specific condition. PM2_Supporting is met.

VCEP rule
This rule should be applied at supporting level. Variant should have an allele frequency of less than 0.00003 (0.003%) in gnomAD or another large sequenced population. If multiple alleles are present within any genetic ancestry group, allele frequency in that group must be <0.00004 (0.004%). Genetic ancestry groups influenced by founder effects (such as Ashkenazi Jewish, Finnish, Amish, Middle Eastern, and “Remaining”) should be ignored.
Evidence considered
  • gnomAD v4.1, variant NM_000546.5:c.854A>T: total AC 0, AN 1,614,150, AF 0, homozygotes 0; African/African American AC 0, AN 75,040, AF 0; all reported ancestry groups have AC 0 and AF 0.
  • ClinGen TP53 VCEP specification v2.4, CSPEC PM2 criterion: PM2 is applied at supporting level for AF <0.00003, with AF <0.00004 in any ancestry group containing multiple alleles and founder-effect groups ignored.
Sources
PP3 ModerateVCEPMet at moderate strength: VCEP Table S2 pre-assigns PP3_moderate for Class C65 and BayesDel 0.453942, exceeding the ≥0.16 threshold. Details ▾Hide ▴
Reasoning

The variant is a TP53 missense change. The governing TP53 VCEP Supplementary Table S2 directly pre-assigns NM_000546:c.854A>T / p.Glu285Val as Class C65 with BayesDel 0.453942 and PP3_moderate. This directly satisfies the VCEP missense PP3_Moderate rule requiring aGVGD Class C65 and BayesDel score ≥ 0.16; the table assignment governs and is not withheld because the supporting prediction is table-based. The table also lists 0.01 for the splice-related field, while the case SpliceAI maximum delta score is 0.006, below the VCEP splice-effect threshold of 0.2; no separate splice PP3 is added or double-counted.

VCEP rule
**Missense variants** _(See flowchart for application of PP3 and BP4 rules for missense variants)_ aGVGD Class C65 and BayesDel score ≥ 0.16
Evidence considered
  • PP3-BP4-codes.xlsx, Supplementary Table S2, matching row: c.854A>T | p.Glu285Val | Class C65 | BayesDel 0.453942 | PP3_moderate | 0.01.
  • The TP53 VCEP PP3 rule for missense variants requires aGVGD Class C65 and BayesDel score ≥ 0.16 for PP3_Moderate; the table's direct PP3_moderate assignment governs this variant.
  • Case SpliceAI result: DS_AG 0.006, DS_AL 0.002, DS_DG 0.0, DS_DL 0.0; maximum delta score 0.006, below the VCEP splice-effect threshold of 0.2.
Still missing
  • No exact c.854A>T, p.Glu285Val, or p.E285V entry was found in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt; that file provides flowchart guidance rather than a per-variant assignment.
  • No exact c.854A>T, p.Glu285Val, or p.E285V entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt; that file covers single-amino-acid in-frame deletions, whereas this variant is missense.
Sources

Not met · 6 · evaluated, threshold not reached

PS4 VCEPNot met: the documented Revised Chompret observation contributes 0.5 PS4 points, below the VCEP Supporting threshold of 1-1.5 points. Details ▾Hide ▴
Reasoning

The exact variant was reported in a de novo germline case with choroid plexus carcinoma and adrenocortical carcinoma (PMID:18762572), and independently in a pediatric adrenocortical carcinoma cohort (PMID:25584008). Applying the governing PS4 points table, the documented clinical-criteria observation contributes 0.5 points (Revised Chompret); the literal comparison is 0.5 < 1 point? yes, so it is below the PS4 Supporting range of 1-1.5 points. The somatic tumor observations in PMID:20436704 and PMID:32113465 do not establish germline case-control enrichment, and PMID:36970330 reports a myeloid case without criterion-bearing prevalence comparison.

VCEP rule
Clinical criteria | Revised Chompret | 0.5 ... PS4 code strength based on total points: ... PS4_Supporting = 1-1.5 points
Evidence considered
  • PS4-Points-Table.pdf, row 'Clinical criteria | Revised Chompret | 0.5'; the same table states PS4_Supporting = 1-1.5 points, PS4_Moderate = 2-3.5 points, PS4 = 4-7.5 points, and PS4_Very Strong = >= 8 points.
  • PMID:18762572, exact germline c.854A>T/p.E285V case: a child presented with choroid plexus carcinoma followed by adrenocortical carcinoma; both parents tested negative, supporting a de novo germline event.
  • PMID:25584008, Table 2 row 58: E285V was recorded as de novo in a pediatric adrenocortical carcinoma cohort.
  • PMID:20436704, exact c.854A>T/p.E285V observation was somatic in one lung adenocarcinoma and absent from matched non-malignant tissue and blood; no germline PS4 comparison was provided.
  • PMID:32113465, TP53 p.Glu285Val was detected by targeted sequencing in one mandibular tumor; no germline testing, segregation, or population-control comparison was reported.
  • PMID:36970330, one myeloid-disorder case had p.E285V at VAF 38%, but the study evaluated p53 immunohistochemistry rather than germline phenotype prevalence or case-control enrichment.
Still missing
  • No case-control enrichment counts or matched-ancestry control comparison for germline c.854A>T/p.E285V were reported in the reviewed publications.
  • PS4-Points-Table.pdf was searched for c.854A>T, p.Glu285Val, and p.E285V; it contains no variant-specific pre-assigned entry.
Sources
PP4 VCEPNot met: the reported VAF is 38%, outside the VCEP PP4 Supporting range of 5-35% and without two 5-25% observations. Details ▾Hide ▴
Reasoning

The TP53 VCEP's PP4 rule is defined by variant allele fraction, not by a generic phenotype-specificity assessment. The exact variant was observed at VAF 38% in PMID:36970330. Applying the literal VCEP range, 5% <= 38% <= 35%? no; no evidence shows at least two independent observations with VAF 5-25%.

VCEP rule
At least 2 independent observations of the variant with VAF 5-25%. ... Observation of the variant with VAF 5-35% (i.e., once or multiple times with VAF >25-35% and/or once with VAF 5-25%)
Evidence considered
  • PMID:36970330, exact c.854A>T/p.E285V observation: 'Specifically, this patient had c.854A > T, p.E285V identified at a variant allele fraction of 38%.'
  • The 38% value does not satisfy the VCEP Supporting inequality 5% <= VAF <= 35%; it also does not provide at least two independent observations in the VAF 5-25% interval.
Still missing
  • No second independent PP4-qualifying observation with VAF 5-25% was identified.
Sources
BA1 VCEPNot met: gnomAD v4.1 reports AF 0 (0/1,614,150 alleles), far below the VCEP BA1 threshold of FAF ≥0.001. Details ▾Hide ▴
Reasoning

The TP53 VCEP BA1 rule requires a filtering allele frequency (FAF) of at least 0.001 in a qualifying continental subpopulation, with at least 2,000 alleles tested and at least 2 variant alleles present. gnomAD v4.1 reports NM_000546.5:c.854A>T (p.Glu285Val) at 0/1,614,150 total alleles, AF 0, with 0 homozygotes; the highest observed continental-subpopulation count is also 0/75,040 in African/African American individuals. Therefore the variant does not meet BA1.

VCEP rule
Filtering allele frequency (FAF) of ≥ 0.001 or 0.1% in gnomAD continental subpopulations of a single genetic ancestry group (excluding genetic ancestry groups influenced by founder effects, such as Ashkenazi Jewish, Finnish, Amish, Middle Eastern, and “Remaining”). Genetic ancestry group must have ≥2,000 alleles tested and a minimum of 2 alleles present.
Evidence considered
  • gnomAD v4.1, variant NM_000546.5:c.854A>T: total AC 0, AN 1,614,150, AF 0, homozygotes 0; highest observed continental-subpopulation value African/African American AC 0, AN 75,040, AF 0.
  • ClinGen TP53 VCEP specification v2.4, CSPEC BA1 criterion: stand-alone benign evidence requires FAF ≥0.001 in a qualifying continental subpopulation, with ≥2,000 alleles tested and a minimum of 2 alleles present.
Sources
BS1 VCEPNot met: gnomAD v4.1 reports AF 0 (0/1,614,150 alleles), below the VCEP BS1 range of FAF ≥0.0003 and <0.001. Details ▾Hide ▴
Reasoning

The TP53 VCEP BS1 rule requires a filtering allele frequency (FAF) of at least 0.0003 but less than 0.001 in a qualifying continental subpopulation, with at least 2,000 alleles tested and at least 2 variant alleles present. gnomAD v4.1 reports AF 0 for this variant, with 0/1,614,150 total alleles and 0/75,040 alleles in the highest observed continental subpopulation. The required frequency range is not reached, so BS1 is not met.

VCEP rule
Filtering allele frequency (FAF) of ≥ 0.0003 but < 0.001 in gnomAD continental subpopulations of a single genetic ancestry group (excluding genetic ancestry groups influenced by founder effects, such as Ashkenazi Jewish, Finnish, Amish, Middle Eastern, and “Remaining”). Genetic ancestry group must have ≥2,000 alleles tested and a minimum of 2 alleles present.
Evidence considered
  • gnomAD v4.1, variant NM_000546.5:c.854A>T: total AC 0, AN 1,614,150, AF 0, homozygotes 0; highest observed continental-subpopulation value African/African American AC 0, AN 75,040, AF 0.
  • ClinGen TP53 VCEP specification v2.4, CSPEC BS1 criterion: strong benign evidence requires FAF ≥0.0003 but <0.001 in a qualifying continental subpopulation, with ≥2,000 alleles tested and a minimum of 2 alleles present.
Sources
BS3 VCEPNot met: the VCEP worksheet assigns PS3 because E285V is non-functional in Kato and LOF in three other eligible assays, not benign functional evidence. Details ▾Hide ▴
Reasoning

The TP53 VCEP Functional-worksheet.xlsx Supplementary Table S3 row for E285V assigns PS3, not BS3: Kato is Non-functional and Funk, Giacomelli, and Kotler are LOF, while Kawaguchi is NA. This is the opposite of the VCEP benign-functional patterns, which require functional or partially functional Kato results together with no LOF across the specified eligible assays. The exact-variant functional study likewise reports absent promoter-transactivation activity and failure to suppress colony growth, so the available functional evidence does not support BS3.

VCEP rule
Functional on Kato et al. data **AND** no loss of function (LOF) by the majority of available eligible assays ... Partially functional on Kato et al. data **AND** no evidence of loss of function (LOF) by **all** available assays
Evidence considered
  • ClinGen TP53 VCEP Functional-worksheet.xlsx, Supplementary Table S3, row E285V: Kato class Non-functional; Funk class LOF; Giacomelli class LOF; Kotler class LOF; Kawaguchi class NA; preliminary functional code PS3, with no BS3 assignment.
  • ClinGen TP53 VCEP functional-code flowchart: BS3 requires functional Kato data with noLOF by the majority of available assays, or partially functional Kato data with noLOF by all available assays; E285V has neither pattern.
  • Russell-Swetek et al. 2008 (PMID:18762572), Functional Characterization of E285V, Fig. 3 and Fig. 4: E285V was inactive in the p53-responsive promoter-reporter assay and did not inhibit colony growth.
Sources
BP4 VCEPNot met: VCEP Table S2 classifies the missense variant as C65 with BayesDel 0.453942, while BP4 excludes C65 and requires BayesDel <0.16. Details ▾Hide ▴
Reasoning

The variant is a TP53 missense change, so BP4 is within scope. The governing VCEP BP4 rule requires a benign BayesDel range and no predicted splice difference; however, it explicitly excludes Class C65 missense variants from BP4, and this variant is Class C65 in the governing Supplementary Table S2. Its BayesDel score is also 0.453942, above the BP4 supporting upper bound of <0.16. The case SpliceAI maximum delta score is 0.006 (<0.2), but that splice result alone cannot establish BP4 for a Class C65 missense variant.

VCEP rule
**Missense variants** _(See flowchart for application of PP3 and BP4 rules for missense variants):_ BayesDel \< 0.16 and > -0.008 irrespective of aGVGD score (except C65, this case do not apply BP4) AND no predicted differences in splicing (SpliceAI \< 0.2) **Single amino acid inframe deletions** _(See single aa BayesDel spreadsheet):_ BayesDel score \< 0.16 AND no predicted splicing impact (Splice AI \< 0.2) **Silent or Intronic Variants (outside ± 1,2 positions):** SpliceAI ≤ 0.1
Evidence considered
  • PP3-BP4-codes.xlsx, Supplementary Table S2, matching row: c.854A>T | p.Glu285Val | Class C65 | BayesDel 0.453942 | PP3_moderate | 0.01; no BP4 assignment is present.
  • The TP53 VCEP BP4 supporting rule requires BayesDel <0.16 and >-0.008 plus SpliceAI <0.2 for missense variants, but states that for Class C65 variants BP4 must not be applied.
  • Case SpliceAI result: maximum delta score 0.006, below 0.2; this does not override the VCEP Class C65 exclusion.
Still missing
  • No exact c.854A>T, p.Glu285Val, or p.E285V entry was found in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt; that file provides flowchart guidance rather than a per-variant assignment.
  • No exact c.854A>T, p.Glu285Val, or p.E285V entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt; that file covers single-amino-acid in-frame deletions, whereas this variant is missense.
Sources

Not assessed · 6 · no assessment recorded

PS1 VCEPNot assessed: no previously VCEP-established pathogenic TP53 variant with the same amino-acid change as p.Glu285Val was identified. Details ▾Hide ▴
Reasoning

The TP53 VCEP permits PS1 when a variant is asserted as Pathogenic following the TP53 VCEP specifications, but the available evidence does not identify a previously established pathogenic TP53 variant with the same amino-acid change as p.Glu285Val. The literature describes E285V as novel in the germline, and the available same-residue E285K report is a different amino-acid change and is not itself a VCEP-established pathogenic comparator for PS1.

VCEP rule
Can be applied to variants asserted as Pathogenic following the _TP53_ VCEP’s specifications.
Evidence considered
  • The TP53 VCEP PS1 rule allows application to variants asserted as Pathogenic following the TP53 VCEP specifications.
  • Russell-Swetek et al. report p.E285V as a novel germline TP53 mutation.
  • Lee et al. report p.E285K at the same residue, but this is a different amino-acid change and the available record does not establish it as a TP53 VCEP-pathogenic comparator.
Still missing
  • A previously established TP53 VCEP-pathogenic variant with the identical amino-acid change is required to evaluate PS1.
Sources
PM1 VCEPNot assessed: residue 285 is outside the six listed codons, while the Cancer Hotspots same-change count needed for the alternative route is unavailable. Details ▾Hide ▴
Reasoning

Residue 285 is outside the TP53 VCEP's explicitly listed codons 175, 245, 248, 249, 273, and 282. The VCEP also permits PM1 for a germline missense variant seen in cancerhotspots.org with at least 10 somatic occurrences for the same amino-acid change, but the available Cancer Hotspots record is only partially parsed and supplies no occurrence count; the separate COSMIC record reports 35 somatic occurrences but is not the VCEP-named Cancer Hotspots source. Therefore the hotspot route cannot be confirmed under the governing rule.

VCEP rule
Missense variants within the following codons using transcript NM\_00546.4: 175, 245, 248, 249, 273, 282. This code weight can also be used for germline missense variants seen in cancerhotspots.org with ≥ 10 somatic occurrences for the same amino acid change.
Evidence considered
  • The VCEP's PM1 codon route lists codons 175, 245, 248, 249, 273, and 282; p.Glu285Val is at codon 285.
  • The Cancer Hotspots record reports that TP53 E285 is a statistically significant hotspot, but its source_data is empty and does not provide the required same-amino-acid somatic occurrence count.
  • COSMIC reports TP53 c.854A>T/p.Glu285Val in 35 somatic occurrences, but the TP53 VCEP rule specifically names cancerhotspots.org for this alternative PM1 route.
  • (cited as evidence_refs, but not a source_registry key: COSMIC)
Still missing
  • Verify the Cancer Hotspots occurrence count for TP53 p.Glu285Val under the VCEP's named hotspot route.
Sources
PM5 VCEPNot assessed: no different residue-285 missense variant was established as pathogenic or clinically supported likely pathogenic under the TP53 VCEP rules. Details ▾Hide ▴
Reasoning

The TP53 VCEP PM5 rule requires one or more different missense variants at the same amino-acid residue that were previously determined to be pathogenic or likely pathogenic according to the TP53 VCEP specifications, with clinical data required for the likely-pathogenic supporting route. The available PM5 candidate search found zero same-residue comparator candidates meeting those requirements. p.E285K is reported in the literature at residue 285, but the available evidence does not establish it as a TP53 VCEP-determined pathogenic or likely pathogenic comparator.

VCEP rule
Missense variant at an amino acid residue where ≥2 different missense variants previously determined to be pathogenic according to the _TP53_ VCEP’s specifications have been seen before. ... Missense variant at an amino acid residue where 1 different missense variant previously determined to be likely pathogenic according to the _TP53_ VCEP’s specifications has been seen before. **The previously seen likely pathogenic variant must have clinical data that demonstrates pathogenicity (i.e. PS2, PS4, PP1) in order for it to count towards PM5\_Supporting code application.**
Evidence considered
  • The TP53 VCEP requires at least two different previously VCEP-pathogenic missense variants for PM5_Strong, one previously VCEP-pathogenic missense variant for PM5_Moderate, or one clinically supported VCEP-likely-pathogenic missense variant for PM5_Supporting.
  • The PM5 comparator search reports zero same-residue candidates, zero expert-panel pathogenic/likely-pathogenic candidates, and no useful candidates.
  • Lee et al. report p.E285K at residue 285, but the available paper does not provide a TP53 VCEP pathogenicity determination for that comparator.
Still missing
  • A different TP53 missense variant at residue 285 with a VCEP-concordant pathogenic or clinically supported likely-pathogenic determination is required.
Sources
PP1 VCEPNot assessed: no affected-relative segregation data or countable meioses are reported, so none of the VCEP's 3-4, 5-6, or ≥7-meiosis thresholds can be evaluated. Details ▾Hide ▴
Reasoning

The evidence documents a de novo proband and negative parental testing but does not report affected relatives carrying the variant or any countable cosegregating meioses. The PP1 threshold cannot therefore be evaluated.

VCEP rule
Cosegregation must be observed in 3-4 meioses in/across 1 or more families ... Cosegregation must be observed in 5-6 meioses in/across 1 or more families ... Cosegregation must be observed in ≥ 7 meioses across > 1 family
Evidence considered
  • PMID:18762572 reports no family history and negative parental testing, but does not provide affected-relative cosegregation or meiosis data.
  • The VCEP LFS cancer table was searched for c.854A>T, p.Glu285Val, and p.E285V; no variant-specific row was found, while its cancer categories govern which affected relatives could be counted.
Still missing
  • No affected relatives with genotype and LFS-associated cancer status are reported, and no countable cosegregating meioses are available.
  • The Table-of-LFS-Cancers-and-Points-for-PS2-and-PP1-Code-Application.pdf has no variant-specific c.854A>T, p.Glu285Val, or p.E285V row; it provides only the governing cancer categories and points.
Sources
BS2 VCEPNot assessed: no qualifying count of unrelated cancer-free females aged ≥60 years from one source is available for the VCEP BS2 rule. Details ▾Hide ▴
Reasoning

The TP53 VCEP BS2 rule requires counts of unrelated females aged at least 60 years without cancer, all from a single source, with specific exclusion of individuals diagnosed with sarcoma at age 61 years or older. The available case evidence contains population allele counts and homozygote counts but no qualifying individual-level female age, cancer-history, relatedness, single-source, or sarcoma-exclusion data. BS2 therefore cannot be evaluated.

VCEP rule
≥ 8 unrelated females who have reached at least 60 years of age without cancer. These individuals all must have come from a single source (single lab, database, etc). Cases cannot be counted across sources. Individuals with a diagnosis of sarcoma ≥ 61 years of age should not be counted towards the BS2 total. ... 4-7 unrelated females who have reached at least 60 years of age without cancer. These individuals all must have come from a single source (single lab, database, etc). Cases cannot be counted across sources. Individuals with a diagnosis of sarcoma ≥ 61 years of age should not be counted towards the BS2 total. ... 2-3 unrelated females who have reached at least 60 years of age without cancer. These individuals all must have come from a single source (single lab, database, etc). Cases cannot be counted across sources. Individuals with a diagnosis of sarcoma ≥ 61 years of age should not be counted towards the BS2 total.
Evidence considered
  • Available gnomAD records provide allele and homozygote counts only and do not provide the individual-level female age, cancer-history, relatedness, source, and sarcoma-exclusion information required by the TP53 VCEP BS2 rule.
  • ClinGen TP53 VCEP specification v2.4, CSPEC BS2 criterion: qualifying observations must be unrelated females aged at least 60 years without cancer and must come from a single source; older sarcoma cases are excluded.
Still missing
  • A single-source dataset identifying unrelated females aged at least 60 years without cancer, including the VCEP sarcoma exclusion, is required.
Sources
BS4 VCEPNot assessed: no affected family member with an LFS-associated cancer is documented as variant-negative, which is required for the VCEP BS4 rule. Details ▾Hide ▴
Reasoning

No affected family member with a documented LFS-associated cancer is reported as testing negative for the variant. Negative parental testing in a de novo case is not lack of segregation in affected family members, so BS4 cannot be applied.

VCEP rule
Lack of segregation in affected family members (i.e. family members diagnosed with LFS-associated cancers as described in Table of LFS Cancers and Points for PS2 and PP1 Code Application).
Evidence considered
  • PMID:18762572 reports that neither parent carried E285V, but this is parental testing in a de novo case and not non-segregation in affected family members.
  • The VCEP LFS cancer table was searched for c.854A>T, p.Glu285Val, and p.E285V; no variant-specific row was found.
Still missing
  • No genotype results for affected relatives are reported, so lack of segregation cannot be demonstrated.
  • The Table-of-LFS-Cancers-and-Points-for-PS2-and-PP1-Code-Application.pdf has no variant-specific c.854A>T, p.Glu285Val, or p.E285V row; it defines the LFS-associated cancers relevant to BS4.
Sources
Not applicable · 12· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: c.854A>T is missense p.Glu285Val, whereas TP53 PVS1 applies to specified null or canonical splice variants. Details ▾Hide ▴
Reasoning

PVS1 is not applicable. The case variant is NM_000546.5:c.854A>T, NP_000537.3:p.(Glu285Val) (p.E285V), a missense substitution in exon 8, not a nonsense, frameshift, canonical splice-site, initiation-codon, or deletion variant covered by the TP53 VCEP PVS1 rule. The VCEP rule states that PVS1 applies to null-variant paths including nonsense or frameshift variants predicted to undergo NMD and specified canonical splice alterations; no PVS1 pre-assigned row for this variant was found in PVS1-Flowchart.pdf.txt or PVS1-Splicing-Worksheet.xlsx.txt.

VCEP rule
Please utilize the PVS1 decision tree for application of PVS1 code. The decision tree details the specific strengths each type of null variant may be applied at.
Evidence considered
  • Case normalization identifies NM_000546.5:c.854A>T as NP_000537.3:p.(Glu285Val)/p.(E285V), a missense variant in exon 8.
  • The TP53 VCEP CSPEC PVS1 rule limits application to specified null-variant and canonical splice-variant paths; this missense substitution is outside those named variant types.
  • Searches of PVS1-Flowchart.pdf.txt and PVS1-Splicing-Worksheet.xlsx.txt found no exact c.854A>T, p.Glu285Val, or p.E285V row.
Still missing
  • No exact c.854A>T, p.Glu285Val, or p.E285V entry found in PVS1-Flowchart.pdf.txt.
  • No exact c.854A>T, p.Glu285Val, or p.E285V entry found in PVS1-Splicing-Worksheet.xlsx.txt.
Sources
PM3 VCEPNot applicable: the TP53 VCEP CSPEC explicitly marks PM3 "Not Applicable". Details ▾Hide ▴
Reasoning

Not applicable: the ClinGen TP53 VCEP Version 2.4 CSPEC criteria entry explicitly marks PM3 as "Not Applicable", so phase, affected-proband observations, and pathogenic variants in trans or cis are not evaluated under this criterion.

VCEP rule
Not Applicable
Evidence considered
  • ClinGen TP53 VCEP Version 2.4 CSPEC criteria entry for PM3: applicability = "Not Applicable".
Sources
PM4 VCEPNot applicable: the TP53 VCEP marks PM4 Not Applicable, and c.854A>T is a missense substitution without a protein-length change. Details ▾Hide ▴
Reasoning

PM4 is not applicable under the TP53 VCEP specification, which explicitly marks PM4 as Not Applicable. The variant is a missense substitution, with no protein-length change or other PM4-eligible consequence under this VCEP rule.

VCEP rule
Not Applicable
Evidence considered
  • The TP53 VCEP CSPEC entry for PM4 has applicability recorded as Not Applicable.
  • Case normalization identifies c.854A>T as p.Glu285Val/p.E285V, a missense substitution rather than a protein-length-changing variant.
Sources
PM6 VCEPNot applicable: the TP53 VCEP dropped PM6 and requires de novo evidence to be evaluated exclusively through PS2. Details ▾Hide ▴
Reasoning

The TP53 VCEP explicitly dropped PM6 and requires de novo evidence to be assessed exclusively through PS2. The available evidence is therefore adjudicated under PS2 rather than PM6.

VCEP rule
To avoid redundancy and increase consistency, the _TP53_ VCEP has opted to drop PM6 and use PS2 exclusively for _de novo_ evidence.
Evidence considered
  • TP53 VCEP v2.4 PS2 instruction states that PM6 was dropped and PS2 is used exclusively for de novo evidence.
Sources
PP2 VCEPNot applicable: the TP53 VCEP explicitly marks PP2 as Not Applicable. Details ▾Hide ▴
Reasoning

The TP53 VCEP marks PP2 as Not Applicable.

VCEP rule
Not Applicable
Evidence considered
  • The TP53 VCEP criteria entry for PP2 states Not Applicable.
Sources
PP5 VCEPNot applicable: the TP53 VCEP explicitly designates PP5 as Not Applicable. Details ▾Hide ▴
Reasoning

The TP53 VCEP explicitly marks PP5 Not Applicable. ClinVar and literature assertions of pathogenicity were therefore not used as PP5 evidence.

VCEP rule
Not Applicable
Evidence considered
  • The CSPEC PP5 entry states 'Not Applicable'; ClinVar and published pathogenic assertions were not converted into PP5 evidence.
Sources
BP1 VCEPNot applicable: the TP53 VCEP explicitly marks BP1 as Not Applicable. Details ▾Hide ▴
Reasoning

The TP53 VCEP marks BP1 as Not Applicable.

VCEP rule
Not Applicable
Evidence considered
  • The TP53 VCEP criteria entry for BP1 states Not Applicable.
Sources
BP2 VCEPNot applicable: the TP53 VCEP CSPEC explicitly marks BP2 "Not Applicable". Details ▾Hide ▴
Reasoning

Not applicable: the ClinGen TP53 VCEP Version 2.4 CSPEC criteria entry explicitly marks BP2 as "Not Applicable", so phase and observations of this variant with another pathogenic variant in cis or trans are not evaluated under this criterion.

VCEP rule
Not Applicable
Evidence considered
  • ClinGen TP53 VCEP Version 2.4 CSPEC criteria entry for BP2: applicability = "Not Applicable".
Sources
BP3 VCEPNot applicable: the TP53 VCEP marks BP3 Not Applicable, and p.Glu285Val is a missense substitution rather than a repeat-region in-frame deletion. Details ▾Hide ▴
Reasoning

BP3 is not applicable under the TP53 VCEP specification, which explicitly marks BP3 as Not Applicable. The variant is the missense substitution p.Glu285Val, not an in-frame deletion in a repetitive region, and the VCEP provides no BP3 path for this consequence.

VCEP rule
Not Applicable
Evidence considered
  • The TP53 VCEP CSPEC entry for BP3 has applicability recorded as Not Applicable.
  • Case normalization identifies c.854A>T as p.Glu285Val/p.E285V, a missense substitution rather than an in-frame deletion in a repetitive region.
Sources
BP5 VCEPNot applicable: the TP53 VCEP explicitly designates BP5 as Not Applicable. Details ▾Hide ▴
Reasoning

The TP53 VCEP explicitly marks BP5 Not Applicable; no alternative benign rule was substituted.

VCEP rule
Not Applicable
Evidence considered
  • The CSPEC BP5 entry states 'Not Applicable'.
Sources
BP6 VCEPNot applicable: the TP53 VCEP explicitly designates BP6 as Not Applicable. Details ▾Hide ▴
Reasoning

The TP53 VCEP explicitly marks BP6 Not Applicable; benign assertions from sources were not substituted for the VCEP rule.

VCEP rule
Not Applicable
Evidence considered
  • The CSPEC BP6 entry states 'Not Applicable'.
Sources
BP7 N/ANot applicable: BP7 covers synonymous or intronic variants, whereas c.854A>T is a missense substitution producing p.Glu285Val. Details ▾Hide ▴
Reasoning

BP7 is limited by the governing TP53 VCEP rule to synonymous (silent) or intronic variants with specified splice-location conditions. NM_000546.5:c.854A>T is a missense variant producing p.Glu285Val, so BP7 is outside its own scope and is not evaluated from the available SpliceAI result.

VCEP rule
A synonymous (silent) outside of the core splice motif (last three nucleotides and first nucleotide of the exon) or intronic variant at or beyond +7 to -21 positions for which SpliceAI predicts no impact to the splice consensus nor the creation of a new splice site (BP4 is met, SpliceAI ≤ 0.1). No requirement to assess for nucleotide conservation for rule application as per evidence and recommendations in Walker et al., 2023  (PMID: 37352859).
Evidence considered
  • The TP53 VCEP BP7 supporting rule applies to a synonymous variant outside the core splice motif or an intronic variant at or beyond +7 to -21 positions; the variant under review is missense.
  • Case normalization identifies NM_000546.5:c.854A>T as NP_000537.3:p.(Glu285Val) / p.(E285V), consequence class missense.
Still missing
  • No exact c.854A>T, p.Glu285Val, or p.E285V entry was found in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt.
  • No exact c.854A>T, p.Glu285Val, or p.E285V entry was found in PP3-BP4-codes.xlsx.txt; the file contains the matching missense row but does not assign BP7.
  • No exact c.854A>T, p.Glu285Val, or p.E285V entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt.
Sources

Identifiers

Gene
TP53
Transcript
NM_000546.5
Coding (HGVS c.)
NM_000546.5:c.854A>T
Protein (HGVS p.)
NP_000537.3:p.(Glu285Val)
GRCh38
chr17:7673766 T>A
GRCh37
chr17:7577084 T>A
Location and type
Exon 8 · missense
ClinVar
12384
COSMIC
COSV52676438

Gene diagram

Every interpreted variant in TP53, mapped onto the exon structure of NM_000546.5. Select a row to find it on the plot.

TP53NM_000546.5
Fetching transcript structure from UCSC…
gnomAD v4.1 0 / 1,614,150 alleles AF 0 · 0 homozygotes
gnomAD v2.1 0 / 251,472 alleles AF 0 · 0 homozygotes
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 0 · 0 / 1,614,150 alleles · 0 hom
No alternate alleles recorded in the displayed ancestry groups.

gnomAD v2.1

AF 0 · 0 / 251,472 alleles · 0 hom
No alternate alleles recorded in the displayed ancestry groups.

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 0; MAF= 0.00000%, 0/1614150 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 0; MAF= 0.00000%, 0/75040 alleles, homozygotes = 0).

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0; MAF= 0.00000%, 0/251472 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 0; MAF= 0.00000%, 0/16254 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat +47 bp
0.002
SpliceAI acceptor gainat +74 bp
0.006
SpliceAI donor lossat -65 bp
0.000
SpliceAI donor gainat +41 bp
0.000
Pangolin splice lossmagnitude shown
-0.003
Pangolin splice gain
0.001

Other predictors

REVEL
0.936
BayesDel
0.454

How the predictions were used

PP3 ModerateVCEPMet at moderate strength: VCEP Table S2 pre-assigns PP3_moderate for Class C65 and BayesDel 0.453942, exceeding the ≥0.16 threshold. Details ▾Hide ▴
Reasoning

The variant is a TP53 missense change. The governing TP53 VCEP Supplementary Table S2 directly pre-assigns NM_000546:c.854A>T / p.Glu285Val as Class C65 with BayesDel 0.453942 and PP3_moderate. This directly satisfies the VCEP missense PP3_Moderate rule requiring aGVGD Class C65 and BayesDel score ≥ 0.16; the table assignment governs and is not withheld because the supporting prediction is table-based. The table also lists 0.01 for the splice-related field, while the case SpliceAI maximum delta score is 0.006, below the VCEP splice-effect threshold of 0.2; no separate splice PP3 is added or double-counted.

VCEP rule
**Missense variants** _(See flowchart for application of PP3 and BP4 rules for missense variants)_ aGVGD Class C65 and BayesDel score ≥ 0.16
Evidence considered
  • PP3-BP4-codes.xlsx, Supplementary Table S2, matching row: c.854A>T | p.Glu285Val | Class C65 | BayesDel 0.453942 | PP3_moderate | 0.01.
  • The TP53 VCEP PP3 rule for missense variants requires aGVGD Class C65 and BayesDel score ≥ 0.16 for PP3_Moderate; the table's direct PP3_moderate assignment governs this variant.
  • Case SpliceAI result: DS_AG 0.006, DS_AL 0.002, DS_DG 0.0, DS_DL 0.0; maximum delta score 0.006, below the VCEP splice-effect threshold of 0.2.
Still missing
  • No exact c.854A>T, p.Glu285Val, or p.E285V entry was found in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt; that file provides flowchart guidance rather than a per-variant assignment.
  • No exact c.854A>T, p.Glu285Val, or p.E285V entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt; that file covers single-amino-acid in-frame deletions, whereas this variant is missense.
Sources
BP4 VCEPNot met: VCEP Table S2 classifies the missense variant as C65 with BayesDel 0.453942, while BP4 excludes C65 and requires BayesDel <0.16. Details ▾Hide ▴
Reasoning

The variant is a TP53 missense change, so BP4 is within scope. The governing VCEP BP4 rule requires a benign BayesDel range and no predicted splice difference; however, it explicitly excludes Class C65 missense variants from BP4, and this variant is Class C65 in the governing Supplementary Table S2. Its BayesDel score is also 0.453942, above the BP4 supporting upper bound of <0.16. The case SpliceAI maximum delta score is 0.006 (<0.2), but that splice result alone cannot establish BP4 for a Class C65 missense variant.

VCEP rule
**Missense variants** _(See flowchart for application of PP3 and BP4 rules for missense variants):_ BayesDel \< 0.16 and > -0.008 irrespective of aGVGD score (except C65, this case do not apply BP4) AND no predicted differences in splicing (SpliceAI \< 0.2) **Single amino acid inframe deletions** _(See single aa BayesDel spreadsheet):_ BayesDel score \< 0.16 AND no predicted splicing impact (Splice AI \< 0.2) **Silent or Intronic Variants (outside ± 1,2 positions):** SpliceAI ≤ 0.1
Evidence considered
  • PP3-BP4-codes.xlsx, Supplementary Table S2, matching row: c.854A>T | p.Glu285Val | Class C65 | BayesDel 0.453942 | PP3_moderate | 0.01; no BP4 assignment is present.
  • The TP53 VCEP BP4 supporting rule requires BayesDel <0.16 and >-0.008 plus SpliceAI <0.2 for missense variants, but states that for Class C65 variants BP4 must not be applied.
  • Case SpliceAI result: maximum delta score 0.006, below 0.2; this does not override the VCEP Class C65 exclusion.
Still missing
  • No exact c.854A>T, p.Glu285Val, or p.E285V entry was found in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt; that file provides flowchart guidance rather than a per-variant assignment.
  • No exact c.854A>T, p.Glu285Val, or p.E285V entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt; that file covers single-amino-acid in-frame deletions, whereas this variant is missense.
Sources
BP7 N/ANot applicable: BP7 covers synonymous or intronic variants, whereas c.854A>T is a missense substitution producing p.Glu285Val. Details ▾Hide ▴
Reasoning

BP7 is limited by the governing TP53 VCEP rule to synonymous (silent) or intronic variants with specified splice-location conditions. NM_000546.5:c.854A>T is a missense variant producing p.Glu285Val, so BP7 is outside its own scope and is not evaluated from the available SpliceAI result.

VCEP rule
A synonymous (silent) outside of the core splice motif (last three nucleotides and first nucleotide of the exon) or intronic variant at or beyond +7 to -21 positions for which SpliceAI predicts no impact to the splice consensus nor the creation of a new splice site (BP4 is met, SpliceAI ≤ 0.1). No requirement to assess for nucleotide conservation for rule application as per evidence and recommendations in Walker et al., 2023  (PMID: 37352859).
Evidence considered
  • The TP53 VCEP BP7 supporting rule applies to a synonymous variant outside the core splice motif or an intronic variant at or beyond +7 to -21 positions; the variant under review is missense.
  • Case normalization identifies NM_000546.5:c.854A>T as NP_000537.3:p.(Glu285Val) / p.(E285V), consequence class missense.
Still missing
  • No exact c.854A>T, p.Glu285Val, or p.E285V entry was found in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt.
  • No exact c.854A>T, p.Glu285Val, or p.E285V entry was found in PP3-BP4-codes.xlsx.txt; the file contains the matching missense row but does not assign BP7.
  • No exact c.854A>T, p.Glu285Val, or p.E285V entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt.
Sources

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01). REVEL score = 0.936. BayesDel score = 0.453942.

7 paper records listed. 3 cited in the classification.

Cited in the classification

  • Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
    Kato S et al. · 2003 Jul 8
    The paper describes the Kato comprehensive TP53 missense-mutant library and yeast-based transactivation assays with multiple promoter reporters, but the extracted text does not explicitly name E285V or provide a variant-specific result for it.
    → PS3 · strong Does not name this variant
    PMID 12826609 ↗
    Source detail
    We constructed 2,314 p53 mutants that represented all possible amino acid substitutions caused by a point mutation throughout the protein

    Location Results, Construction of 2,314 Distinct p53 Missense Mutations

    Context Comprehensive TP53 missense-mutant library assessed primarily with yeast-based sequence-specific transactivation assays using eight p53-responsive promoter elements, with selected mutants additionally tested in Saos-2 human osteosarcoma cells.

  • Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma.
    Russell-Swetek A et al. · 2008 Sep
    The exact TP53 E285V variant was reported as a de novo germline mutation in a child with choroid plexus carcinoma followed by adrenocortical carcinoma; the variant was detected in the proband and neither parent carried it.
    → PS2 · strong → PS3 · strong Names this variant
    PMID 18762572 ↗
    Source detail
    The ACC and CPC samples remained heterozygous for the TP53-E285V mutation, indicating that there was no selection against the wild-type allele. No mutation was detected in either parent, suggesting that the E285V mutation arose de novo in the proband.

    Location Results, 'Association of a Novel Germline TP53-E285V Mutation with ACC and CPC'; Fig. 1; Discussion

    Context Case report with sequencing of peripheral blood lymphocyte, adrenocortical carcinoma, and choroid plexus carcinoma DNA; both parents were tested for the variant.

  • Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.
    Wasserman JD et al. · 2015 Feb 20
    The pediatric adrenocortical carcinoma cohort identifies TP53 E285V as a de novo germline mutation in a child without a significant family cancer history and reports the variant in Table 2, pedigree 58.
    → PS2 · strong → PS3 · strong Names this variant
    PMID 25584008 ↗
    Source detail
    Of the remaining eight children with TP53 variants and no family cancer history, four patients had de novo mutations (Y163C, H193P, C275X, and E285V)

    Location Results, 'Residual TP53 Activity May Underlie Low-Penetrance Alleles'; Table 2, pedigree 58

    Context Pediatric adrenocortical carcinoma cohort of 88 children with germline TP53 sequencing; Table 2 reports the E285V pedigree and de novo status.

Other recorded publications

  • Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients.
    Alsner J et al. · 2000
    No paper-specific finding is recorded.
    PMID 11051239 ↗
  • Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS et al. · 2012
    This paper reports TP53 p.E285K, a different missense substitution at the same residue as the assessed p.E285V variant, in two unrelated Chinese women with early-onset breast cancer; it does not report p.E285V or establish p.E285K under the TP53 VCEP specifications as pathogenic or likely pathogenic.
    Does not name this variant
    PMID 22507745 ↗
    Quoted passage
    This mutation was found in two unrelated Chinese individuals

    Results, subsection “Mutation TP53 c.853 G > A (p. E285K)”; Figure 2b

  • High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort.
    Mitchell G et al. · 2013
    No paper-specific finding is recorded.
    PMID 23894400 ↗
  • Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.
    No paper-specific finding is recorded.
    PMID 28492532 ↗

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 0; MAF= 0.00000%, 0/1614150 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 0; MAF= 0.00000%, 0/75040 alleles, homozygotes = 0).

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 0; MAF= 0.00000%, 0/251472 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 0; MAF= 0.00000%, 0/16254 alleles, homozygotes = 0).

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant has been reported in ClinVar as Pathogenic (1 clinical laboratory). (ClinVarID = 12384)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01). REVEL score = 0.936. BayesDel score = 0.453942.

Functional

OncoKB identified variant-specific curated literature and context relevant to functional review; biological-effect context: Loss-of-function; curated oncogenicity label: Oncogenic.

Somatic

This variant lies in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV52676438, n = 35 times).

Cancer Hotspots

This variant lies in a statistically significant hotspot.